Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an impressive ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort ...

A group of pharma companies and Duchenne UK are collaborating to improve the chances of new treatments for Duchenne muscular dystrophy gaining NICE approval. Roche, Pfizer, PTC Therapeutics, and ...